The Washington Supreme Court has agreed to consider the Washington Farm Bureau’s claim that the Department of Ecology shirked ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Born in Wellington in 1944, Peter struggled at school with what would now be recognised as dyslexia. He left Wellington Tech at age 15 and worked as a tele ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

We recently published a list of 10 Firms Kick Off Trading Week Stronger. In this article, we are going to take a look at ...